Retension Pharmaceuticals just filed for IPO. The clinical-stage biopharma is developing RTN-001, a once-daily oral PDE-5 inhibitor for uncontrolled hypertension, now in Phase 2b. Net loss: -$6.3M.

The pipeline story: RTN-001 aims to lower blood pressure by potentiating nitric oxide signaling. It's been studied in 265+ subjects, and the company inked a Phase 2b collaboration with the Cleveland Clinic. Proceeds go toward finishing the Phase 2b trial of RTN-001 in uHTN and preparing for a planned Phase 3, with the rest earmarked for general corporate purposes. Risks are the classic clinical-stage set: limited operating history, significant losses since inception, no revenue yet, and the stark reality that if RTN-001 fails to win approval, revenue may never materialize. Bottom line: a single-asset hypertension play with a patent runway to 2044 and fresh Series B cash behind it. Early-stage, binary, and worth watching only if you can stomach trial risk.

The pipeline story: RTN-001 aims to lower blood pressure by potentiating nitric oxide signaling. It's been studied in 265+ subjects, and the company inked a Phase 2b collaboration with the Cleveland C